<논문>
Yoo JH*, Kim S*, Park Y, Park S, Chung CH, Kim JH, Kwak SH **, Kim G**Three-Year Glycemic Trajectories in Subgroups with Type 1 Diabetes at Risk for Suboptimal Glycemic Control: A Multicenter Continuous Glucose Monitoring Study. Diabetes Care. 2026, Accepted
Yoo JH*, Kim S*, Park Y, Jin S-M, Chung CH, Kwak SH, Kim JH**, Kim G**Comparative Analysis of Short-Term (14-Day) and Long-Term (90-Day) Continuous Glucose Monitoring Metrics: Implications for Hypoglycemia in Type 1 Diabetes Mellitus. Diabetes Metab J. 2026, Accepted
Yoo JH, Kim S, Kim Y, Jin SM, Kim JH. Retrospective Validation of a Stage 5 Decision Support Algorithm Using Clinical Trial Data From Stage 4 Smart Insulin Pens. J Diabetes Sci Technol. 2026 Aug 3:19322968261471490. doi: 10.1177/19322968261471490. Online ahead of print.
Yoo JH*, Kim S*, Park Y, Jin S-M, Chung CH, Kwak SH, Kim JH**, Kim G**, Determinants of Discordance Between Estimated and Measured HbA1c: The Role of Active Time in 14-Day Continuous Glucose Monitoring Data, Diabetes Metab J. 2026, Accepted
Yoo JH*, Jun JE*, Kwak SH**, Kim JH**, Improved Glycemic Control in Insulin-treated Individuals with Poorly Controlled Type 2 Diabetes through Combined Structured Education with Real-time Continuous Glucose Monitoring, J Diabetes Sci Technol. 2026 May;20(3):875-885.
Yoo JH*, Lee Y-B*, Jun JE, Lee K-N, Han K, Income and risk of type 2 diabetes incidence varied associations according to obesity status: a nationwide study, BMC Public Health, 2026 Mar 18;26(1):1374.
Yoo JH*, Moon SJ*, Park C-Y, Kim JH, Differences between Glycated Hemoglobin and Glucose Management Indicator in Real-Time and Intermittent Scanning Continuous Glucose Monitoring in Adults with Type 1 Diabetes. J Diabetes Sci Technol. 2026 Jan;20(1):103-112.
Kim JY*, Yoo JH*, Kim NH, Kim JH, Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes, J Diabetes Sci Technol. 2026 May;20(3):775-786.
Yoo JH, APOC3 (apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3) Inhibitors: Current Evidence and Future Directions, Cardiovascular Prevention and Pharmacotherapy, 2025 Nov
Yoo JH*, Kim JY*, Kim JH. Effectiveness of Predicted Low-Glucose Suspend Pump Technology in the Prevention of Hypoglycemia in People With Type 1 Diabetes: Real-World Data Using DIA:CONN G8. Diabetes Metab J. 2025 Jan;49(1):144-149.
Yoo JH, Yang SH, Jin S-M, Kim JH. Optimal Coefficient of Variance Threshold to Minimize Hypoglycemia Risk in Individuals with Well-Controlled Type 1 Diabetes. Diabetes Metab J. 2024 May;48:429-439
Yoo JH, Kim JH. Smart Insulin Pen: Managing Insulin Therapy for People with Diabetes in the Digital Era. J Korean Diabetes. 2023 Dec;24(4):190-198.
Kim JY*, Yoo JH*, Kim JH. Comparison of glycemic risk index (GRI) with time in range for assessing glycemic quality. Diabetes Technol Ther. 2023 Dec;25(12):883-892.
Yoo JH, Kim JH. Benefits of continuous glucose monitoring in pregnancy. Endocrinol Metab (Seoul). 2023 Oct;38(5):472-481.
Yoo JH, Kim JY, Kim JH. Association Between Continuous Glucose Monitoring-Derived Glycemia Risk Index and Albuminuria in Type 2 Diabetes. Diabetes Technol Ther. 2023 Oct;25(10):726-735.
Yoo JH, Kim JH. Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control. Diabetes Metab J. 2023 Jan;47(1):27-41.
Yoo JH, Kim G, Lee HJ, Sim KH, Jin S-M, Kim JH. Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes: A randomized controlled trial. Diabetes Res Clin Pract. 2022 Jan 19;184:109209
Yoo JH, Yang SH, Kim G, Kim JH. Glucose Management Indicator for People with Type 1 Asian Diabetes Is Different from That of the Published Equation: Differences by Glycated Hemoglobin Distribution. Diabetes Technol Ther. 2021 Nov; 23(11):745-752
Yoo JH, Kim JH. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control. Diabetes Metab J. 2020 Dec;44(6):828-839.
Yoo JH, Kang M, Kim G, Hur KY, Kim JH, Sinn DH, Jin SM. Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. J Diabetes Investig. 2021 Jul;12(7):1252-1262.
Lee J*, Yoo JH*, Kim HS, Cho YK, Lee Y, Lee WJ, Park JY, Jung CH. C1q/TNF-related protein-9 attenuates palmitic acid-induced endothelial cell senescence via increasing autophagy. Mol Cell Endocrinol. 2021 Feb 5;521:111114.
Yoo JH, Park SW, Jun JE, Jin SM, Hur KY, Lee MK, Kang M, Kim G, Kim JH. Relationship between low skeletal muscle mass, sarcopenic obesity and left ventricular diastolic dysfunction in Korean adults. Diabetes Metab Res Rev. 2021 Jan;37(1):e3363.
Yoo JH, Choi MS, Ahn J, Park SW, Kim Y, Hur KY, Jin SM, Kim G, Kim JH. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes. Diabetes Technol Ther. 2020 Oct;22(10):768-776.
Yoo JH, Kim G, Park SW, Choi MS, Ahn J, Jin SM, Hur KY, Lee MK, Kang M, Kim JH. Effects of low skeletal muscle mass and sarcopenic obesity on albuminuria: a 7-year longitudinal study. Sci Rep. 2020 Apr 1;10(1):5774.
Yoo JH, Cho YK, Lee J, Kim HS, Kang YM, Jung CH, Park JY, Lee WJ. Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study. Diabetes Ther. 2019 Aug;10(4):1453-1463.
Yoo JH, Kang YM, Cho YK, Lee J, Jung CH, Park JY, Ryu OH, Kim HK, Lee WJ. The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects. Clin Endocrinol (Oxf). 2019 Aug;91(2):271-277.
Kang B, Oh R, Kim T, Yoo JH, Kang D, Kim G, Jin SM, Chung MJ, Kim JH. Association of Variability of Monthly Continuous Glucose Monitoring-Derived Metrics With Diabetic Kidney Disease in Type 1 Diabetes. Diabetes Obes Metab. 2026 Jul 14. doi: 10.1111/dom.71117. Online ahead of print.
Kim JY, Kim NH, Kwak SH, Jung CH, Kang ES, Moon SJ, Kwon SY, Yoo JH, Kim YH, Lee TM, Yan CI, Kim JH, Jin S-M, Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol, Endocrinol Metab (Seoul). 2026 Jun;41(3):393-404.
Cho YK, Hong SM, Park JH, Lee B-W, Yoo JH, Kim JH, Chun SW, Hwang Y-C, Song K-H, Lee WJ, Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP‐4 inhibitors: A multicentre, phase 4 randomized controlled trial, Diabetes Obes Metab. 2025 Nov;27(11):6375-6385.
Kim JY, Jin S-M, Kim G, Kim KS, Kim WJ, Moon SJ, Yoo JH, Lee DY, Lee SE, Jun JE, Kim JH, A Position Statement on Diabetes with β-Cell Failure. J Korean Diabetes. 2024;25(3):124-134.
Kin JY, Jin S-M, Kang ES, Kwak SH, Yang Y, Yoo JH, Bae JH, Moon JS, Jung CH, Bae JC, Suh S, Moon SJ, Song SO, Chon S, Kim JH, Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial. Diabetologia. 2024 Jul;67(7):1235-1244.
Yang YS, Lee SH, Kim JH, Yoo JH, Lee JH, Lee SY, Hong AR, Lee DH, Koh JM, Kim JH, Kim SW. Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism. Endocrinol Metab (Seoul). 2021 Aug;36(4):875-884.
Choi MS, Jun JE, Park SW, Yoo JH, Ahn J, Kim G, Jin SM, Hur KY, Lee MK, Kim JH. Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy. Diabetes Metab J. 2021 May;45(3):349-357.
Lee SE, Park SW, Choi MS, Kim G, Yoo JH, Ahn J, Jun JE, Park HS, Hyun D, Cho SK, Ko SE, Kim BJ, Kim JW, Yoon HK, Koh JM, Lee SH, Kim JH. Primary aldosteronism subtyping in the setting of partially successful adrenal vein sampling. Ther Adv Endocrinol Metab. 2021 Feb 13;12:2042018821989239.
Cho YK, Kang YM, Yoo JH, Lee J, Park JY, Lee WJ, Kim YJ, Jung CH. Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study. Metabolism. 2019 Aug;97:50-56.
Cho YK, Lee J, Kang YM, Yoo JH, Park JY, Jung CH, Lee WJ. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. PLoS One. 2019 Aug 1;14(8):e0220667.
Cho YK, Kang YM, Yoo JH, Lee J, Lee SE, Yang DH, Kang JW, Park JY, Jung CH, Kim HK, Lee WJ. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep. 2018 Aug 13;8(1):12004.
<저서>
2022-10, 연속혈당측정기를 활용한 인슐린 요법: 다회주사인슐린 주사요법 중인 2형 당뇨인용, 마루도서
2022-10, 연속혈당측정기를 활용한 인슐린 요법: 기저 인슐린 주사요법 중인 2형 당뇨인용
2021-11, Stroke revisited: Diabetes in stroke. Springer Verlag, Singapore; 1 st ed. 2021 edition
2020-2 술술~ 풀리는 쉬운 당 조절법, 인슐린 펌프로 고수되기, 마루도서
2020-2, 술술~ 풀리는 쉬운 당 조절법, 탄수화물 섭취량 알고 먹자, 마루도서